# Pizarra — PT-pseudo_132e0000c0e0 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_132e0000c0e0
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 13.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 0.52 ng/mL/yr
  - Prior PSA: 13.3 ng/mL
  - Prostate volume: 68.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83881855 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Chronic kidney disease
  - Problem list / PMHx: Chronic kidney disease
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 13.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 68 mL. csPCa 0.84.

Vitals: weight 91 kg, height 179 cm, BMI 28.4, BP 107/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2010).

Chief complaint: A clinical review was requested after a previous negative biopsy and a subsequent rise in PSA levels to 13.6 ng/mL.

History: At 57 years of age, this retired greenhouse horticulturalist is married and living with his partner. Adult children visit weekly. Clinical investigation began in late 2023 due to an upward PSA trajectory. Current symptom burden includes moderate lower urinary tract complaints, registering an IPSS score of 12. Nocturia occurs twice per night, accompanied by a somewhat diminished stream, yet hematuria and pelvic discomfort are absent. Chronic kidney disease defines his medical background, currently showing an eGFR below 60 mL/min/1.73m². He maintains a daily twenty-minute walking regimen and abstains from alcohol entirely. Smoking cessation occurred in 2010, concluding a thirty-five pack-year habit. Outside urological concerns, vascular surgery addressed symptomatic varicose veins recently, while dermatology treated actinic keratoses the previous month. His residence sits more than ninety minutes from the hospital, leading him to favor telephone updates when feasible, with his sister listed as next of kin.

Physical examination: DRE: Normal examination. The prostate presents as symmetrically enlarged yet benign, characterized by a smooth, firm consistency without palpable nodules or asymmetry. Vital parameters remain stable, recording a blood pressure of 107/77 mmHg and a heart rate of 64 bpm. General inspection reveals no pallor, jaundice, or peripheral lymphadenopathy.

Patient info: retired greenhouse horticulturalist; Married; Lives with partner; adult children visit weekly.
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Vascular surgery — varicose veins consult; Dermatology — actinic keratosis check.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.76 +/- 0.17   (95% CI 0.37-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.14  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 6.5 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=13.6, age=57.0, psad=0.2, dre_ord=0.0, vol=68.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the visible panel data (PI-RADS=5, PSA=13.6, PSA density=0.2, DRE=Normal, Volume=68.0 mL, Prior Biopsy=Negative, csPCa probability=0.83881855). It failed to incorporate the crucial context of the PSA velocity (0.52 ng/mL/yr), the patient's history of Chronic Kidney Disease (eGFR < 60 mL/min/1.73m²), and the clinical symptoms (IPSS=12, nocturia), which are critical for risk stratification beyond the raw numbers.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.76 +/- 0.17). This suggestion could be wrong because the statistical model did not account for the potential for overdiagnosis given the high csPCa probability (0.84) combined with a normal DRE, or the impact of the patient's CKD on treatment tolerance. The wide error bar (0.17) suggests high aleatoric uncertainty, meaning the nearest labelled cases disagree significantly, and the model might be over-relying on the PI-RADS 5 score without adequately weighting the clinical context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology consultation notes
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline suggests repeating biopsy when an mpMRI shows a PI-RADS 4-5 lesion, but also notes that factors like low PSA-D or low PSA velocity can be used to individualize the need for repeat biopsy during active surveillance.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Report Source: Spaarne Gasthuis Radiology | Date: 28 Jan 2025 | Study: Multiparametric MRI of the Prostate
The report identifies a PI-RADS 5 lesion in the right anterior mid-gland measuring approximately 14 mm, with restricted diffusion and early, rapid focal enhancement. It notes no evidence of extraprostatic extension or seminal vesicle invasion.

get_psa_trend
The PSA trend shows a rising trajectory: 4.4 ng/mL (Dec 2023) -> 5.8 ng/mL (Mar 2024) -> 7.7 ng/mL (Jul 2024) -> 10.3 ng/mL (Oct 2024) -> 13.6 ng/mL (Feb 2025).

get_lab_results
PSA: 13.6 ng/mL (19 Dec 2024). Free PSA: 3.72 ng/mL (27% Free PSA). eGFR: <60 mL/min/1.73m2 (L).

get_previous_notes
The previous note from Aug 2023 confirms a prior negative biopsy performed in July 2023, which prompted a directive to recheck PSA levels in six months.

NOT RETRIEVED
The pathology report was not retrieved, which means the ISUP grade or Gleason score of the prior negative biopsy is unknown.

WHAT THE EVIDENCE SUPPORTS
Findings that argue FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion (14 mm) in the right anterior mid-gland.
- PSA trend: Significant rising trajectory, reaching 13.6 ng/mL.
- Previous notes: Patient was directed to recheck PSA levels after a prior negative biopsy.

Findings that argue AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the high-risk PI-RADS 5 finding and the concerning PSA velocity, aligning with the expert protocol criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is strongly supported by the guideline criterion for a PI-RADS 5 lesion following a prior negative biopsy. This is driven by the high-risk imaging finding (PI-RADS 5) and the concerning PSA trajectory, which showed a significant rise to 13.6 ng/mL. The evidence report confirmed the PI-RADS 5 lesion and the rising PSA trend, which aligns with the expert protocol and overturns the statistical prior's uncertainty by providing a specific, high-risk finding.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
